| Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewing | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brachytherapy for osteosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dacarbazine for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for dermatofibrosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Definitive radiotherapy for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + oleclumab for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + BEVACIZUMAB + Paclitaxel for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Doxorubicin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + Eribulin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + PEMBROLIZUMAB for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 + TRASTUZUMAB DERUXTECAN for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-102 subcutaneous (SC) for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HS-20093 for osteosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Intensity-modulated radiation therapy (IMRT) for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + Temozolomide for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iscador*P for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivonescimab for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lifileucel for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lifileucel for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lurbinectedin for leiomyosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Naxitamab for sarcoma, ewing | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NIVOLUMAB + Catequentinib for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab + trabectedin for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Onfekafusp alfa for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for carcinosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for sarcoma, ewing | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for dermatofibrosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality of Life + Functional outcome + preoperative for sarcoma, synovial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + TRABECTEDIN for leiomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + TRABECTEDIN for liposarcoma, myxoid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Regorafenib for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Siremadlin + PAZOPANIB for sarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talimogene laherparepvec + nivolumab + trabectedin for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vinorelbine for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|